The landscape of cancer research and drug development is constantly evolving, with groundbreaking advancements shaping the future of oncology treatments. Understanding not only the science but the regulatory concerns, legal challenges, and market climate for this industry is critical.
One of the most significant changes in recent years has been the introduction of artificial intelligence (AI) to drug research and development. This technology is revolutionizing how pharmaceutical companies operate, from initial drug discovery to post-marketing analysis. In the oncology field in particular, AI has the potential to make an important difference by helping to identify improvements to therapeutic agents and reduce approval times necessary to bring life-saving products to patients. However, its implementation includes potential risks, which must be mitigated to assure positive outcomes and acceptance by clinicians.
Click here to view the full article